A team of research scientists from VTT Technical Research Centre of Finland,
the University of Turku and the University of Eastern Finland has discovered a
previously unknown Cent-1 molecule that kills cancer cells. Their research
also shows that new cancer drug candidates can be identified faster and at
lower cost by using computer-assisted and cell-based screening of compounds.
The objective of the research project led by Marko Kallio, Principal Scientist
at VTT, was to accelerate the drug development process by identifying new
compounds that would possess similar binding properties and cellular
phenotype , but a different chemical structure, as the selected drugs in
clinical use or investigational compounds in development.
The scientists combined computer-based screening and cell-based assays to
create a method that can significantly accelerate drug discovery and thereby
lower development costs. It is highly likely that the new compounds identified
using this method have not yet been patented.
The research team conducted a computer-assisted screening of 65,000 compounds
and cell-based assays on the 150 highest scoring hit compounds, before
identifying the Cent-1 molecule. The Cent-1 molecule kills cancer cells
through a mechanism similar to that of the template drug Rigosertib that is
currently under commercial development. However, since the chemical structure
of the Cent-1 compound differs from Rigosertib, there are no major obstacles
to further development.
What makes the study also significant is evidence that Rigosertib did not
inhibit its reported target genes; there is reason to believe that the drug
has a different mechanism of action at molecular level than anticipated. This
drug discovery related study was published in the Molecular Cancer
Therapeutics in April 2014.
Development of new drugs is an expensive and time-consuming process. It
usually takes around 10–15 years to complete and costs several hundreds of
millions of euros. In addition, risks associated with the usability,
therapeutic efficacy and market share of medicinal substances are usually
realised only in the final stages of drug development.